Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JVS-100 in advanced peripheral artery disease
NCT02544204Phase 2Unknown
- Sponsor
- Juventas Therapeutics
- Start
- Nov 2015
- Primary completion
- Sep 2017
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of JVS-100 in peripheral artery disease (PAD), sponsored by Juventas Therapeutics. Status: unknown.
02
Drugs
JVS-100
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT02544204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02544204.